Skip to main content
SpringerLink
Log in

Antifungal Agents

  • Chapter
  • First Online:
Interactions of Yeasts, Moulds, and Antifungal Agents

Abstract

This chapter lists the formulations for and primary uses of, and the mechanisms and spectrum of activity for the major classes of antifungal agents. Interpretation of laboratory results and comments about toxicity or adverse effects are noted where appropriate. When resistance has been found for the agents, this will be described with references to instances where it has been reported.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aperis G, Mylonakis E (2006) Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 15:579–602

    Article  PubMed  CAS  Google Scholar 

  2. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH (2001) In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 45:27–30

    Article  Google Scholar 

  3. Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, Paetznick V, Gordon D, Wallace T, Rex JH (2002) In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol 40:1406–1412

    Article  PubMed  CAS  Google Scholar 

  4. Atkinson BJ, Lewis RE, Kontoyiannis DP (2008) Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol 46:541–546

    Article  PubMed  CAS  Google Scholar 

  5. Barasch A, Griffin AV (2008) Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol 3:265–269

    Article  PubMed  CAS  Google Scholar 

  6. Barchiesi F, Calabrese D, Sanglard D, Falconi Di Francesco L, Caselli F, Giannini D, Giacometti A, Gavaudan S, Scalise G (2000) Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 44:1578–1584

    Article  PubMed  CAS  Google Scholar 

  7. Blum G, Perkholder S, HAAS H, Schrettl M, Wurzner R, Dierich MP, Lass-Flori C (2008) Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 52:1553–1555

    Article  PubMed  CAS  Google Scholar 

  8. Borelli C, Korting HC, Bodeker RH, Neumeister C (2010) Safety and efficacy of sertaconazole nitrate cream 2% in the treatment of tinea pedis interdigitalis: a subgroup analysis. Cutis 85:107–111

    PubMed  Google Scholar 

  9. Burgess MA, Bodey GP (1972) Clotrimazole (Bayb 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother 2:423–426

    Google Scholar 

  10. Cleary JD (2008) Echinocandins: pharmacokinetic and therapeutic issues. Curr Med Res Opin 25:1741–1749

    Google Scholar 

  11. CLSI document M38A-2 (2008a) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard, 2nd edn. Clinical and Laboratory Standards Institute, Wayne, PA

    Google Scholar 

  12. CLSI document M27 A3 (2008b) Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd edn. Clinical and Laboratory Standards Institute, Wayne, PA

    Google Scholar 

  13. Coskun B, Saral Y, Akpolat N, Ataseven A, Cicek D (2004) Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature. Mycopathologica 158:53–56

    Article  Google Scholar 

  14. Cross EW, Park S, Perlin DS (2000) Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist 6:155–161

    Article  PubMed  CAS  Google Scholar 

  15. Darkes MJ, Scott LJ, Goa KL (2003) Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol 4:39–65

    Article  PubMed  Google Scholar 

  16. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA (2003) Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41:3623–3626

    Article  PubMed  CAS  Google Scholar 

  17. Favre B, Ghannoum MA, Ryder NS (2004) Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. Med Mycol 42:525–529

    Article  PubMed  CAS  Google Scholar 

  18. Fromtling RA (1988) Overview of medically important antifungal azoles derivatives. Clin Microbiol Rev 1:187–217

    PubMed  CAS  Google Scholar 

  19. Ghannoum MA, Herbert J, Isham N (2011) Repeated exposure of Candida spp. to miconazole demonstrates no development of resistance. Mycoses 54:e175–e177

    Article  PubMed  CAS  Google Scholar 

  20. Girmenia C (2009) New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 18:1354–1384

    Article  Google Scholar 

  21. Goodman AG, Goodman LS, Rall TW, Murad F (eds) (1985) Goodman and Gilman’s the pharmacological basis of therapeutics, 7th edn. Macmillan Publishing Co, New York

    Google Scholar 

  22. Gupta AK (2001) Ciclopirox: an overview. Int J Dermatol 40:305–310

    Article  PubMed  CAS  Google Scholar 

  23. Herbrecht R, Rajagopalan S, Danna R, Papadopoulos G (2010) Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis. Curr Med Res Opin 26:2457–2464

    Article  PubMed  Google Scholar 

  24. Isham N, Ghannoum MA (2010) Antifungal activity of miconazole against recent Candida strains. Mycoses 53:434–437

    Article  PubMed  CAS  Google Scholar 

  25. Jerajani HR, Amladi ST, Bongale R, Adepu V, Tendolkar UM, Sentamilselvi G, Janaki VR, Janaki C, Vidhya S, Marfatia YS, Patel K, Sharma N, Cooverj ND (2000) Evaluation of clinical efficacy and safety of once daily topical administration of 1% oxiconazole cream and lotion in dermatophytosis: an open label, non-comparative multicenter study. Indian J Dermatol Venereol Leprol 66:188–192

    PubMed  CAS  Google Scholar 

  26. Johnson LB, Kaufman CA (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630–637

    Article  PubMed  CAS  Google Scholar 

  27. Kaufman CA, Carver PL (2008) Update on echinocandin antifungals. Semin Respir Crit Care Med 28:211–219

    Article  Google Scholar 

  28. Kokjohn K, Bradley M, Griffiths B, Ghannoum M (2003) Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol 42:11–17

    Article  PubMed  CAS  Google Scholar 

  29. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191:1350–1360

    Article  PubMed  Google Scholar 

  30. Korting HC, Schollmann C (2009) The significance of itraconazole for treatment of fungal infections of skin, nails, and mucous membranes. J Dtsch Dermatol Ges 7:11–20

    PubMed  Google Scholar 

  31. Leyden J (1998) Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 38:S42–S47

    Article  PubMed  CAS  Google Scholar 

  32. Lynch ME, Sobel JD (1994) Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 32:267–274

    Article  PubMed  CAS  Google Scholar 

  33. Maeda T, Takase M, Ishibashi A et al (1991) Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent. Yakugaku Zasshi 111:126–137

    PubMed  CAS  Google Scholar 

  34. Meadows-Oliver M (2009) Tinea capitis: diagnostic criteria and treatment options. Dermatol Nurs 21:281–286

    PubMed  Google Scholar 

  35. McClellan KJ, Wiseman LR, Markham A (1999) Terbinafine. An update of its use in superficial mycoses. Drugs 58:179–202

    Article  PubMed  CAS  Google Scholar 

  36. Nagappan V, Deresinski S (2007) Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 45:1610–1617

    Article  PubMed  CAS  Google Scholar 

  37. Neubert RH, Gensbugel C, Jackel A, Warewig S (2006) Different physiochemical properties of antimycotic agents are relevant for penetration into and through human nails. Pharmazie 61:604–607

    PubMed  CAS  Google Scholar 

  38. Nguyen MH, Clancy CJ, Yu VL, Yu YV, Morris AJ, Snydman DR, Sutton DA, Rinaldi MG (1998) Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 177:425–430

    Article  PubMed  CAS  Google Scholar 

  39. Oren I (2005) Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 40:770–771

    Article  PubMed  Google Scholar 

  40. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH (2003) Amphotericin B: time for a new “gold standard”. Clin Infect Dis 37:415–425

    Article  PubMed  CAS  Google Scholar 

  41. Peman J, Canton E, Espinel-Ingroff A (2009) Antifungal resistance mechanisms. Expert Rev Anti Infect Ther 7:453–460

    Article  PubMed  CAS  Google Scholar 

  42. Petranyi G, Ryder NS, Stutz A (1984) Allylamine derivatives: a new class of synthetic antifungal agents inhibiting squalene epoxidase. Science 224:1239–1241

    Article  PubMed  CAS  Google Scholar 

  43. Pfaller MA, Boyken L, Hollis RJ et al (2008) In vitro susceptibility os invasive isolates of Candida spp. To anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46:150–156

    Article  PubMed  CAS  Google Scholar 

  44. Physicians Desk Reference, www.pdr.net

  45. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH (2008) Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 42:1429–1438

    Article  PubMed  CAS  Google Scholar 

  46. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43:2155–2162

    Article  PubMed  CAS  Google Scholar 

  47. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G (2005) Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 49:668–679

    Article  PubMed  CAS  Google Scholar 

  48. Seidman LS, Skokos CK (2005) An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. Infect Dis Obstet Gynecol 13:197–206

    Article  PubMed  CAS  Google Scholar 

  49. Singal A (2008) Butenafine and superficial mycoses: current status. Expert Opin Drug Metab Toxicol 4:999–1005

    Article  Google Scholar 

  50. Sterling JB, Heymann WR (2000) Potassium iodide in dermatology: a 19th century drug for the 21st century—uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol 43:691–697

    Article  PubMed  CAS  Google Scholar 

  51. Sucher AJ, Chahine EB, Balcer HE (2009) Echinocandins: the newest class of antifungals. Ann Pharmacother 43:1647–1657

    Article  PubMed  CAS  Google Scholar 

  52. Syed TA, Maibach HI (2000) Butenafine hydrochloride: for the treatment of interdigital tinea pedis. Expert Opin Pharmacother 1:467–473

    Article  PubMed  CAS  Google Scholar 

  53. Thompson GR, Cadena J, Patterson TF (2009) Overview of antifungal agents. Clin Chest Med 30:203–215

    Article  PubMed  Google Scholar 

  54. Togni G, Mailland F (2010) Antifungal activity, experimental infections and nail permeation of an innovative ciclopirox nail lacquer based on a water-soluble biopolymer. J Drugs Dermatol 9:525–530

    PubMed  Google Scholar 

  55. Vazquez JA (2005) Anidulafungin: a new echinocandin with a novel profile. Clin Ther 27:657–673

    Article  PubMed  CAS  Google Scholar 

  56. Verweij PE, Howard SJ, Melchers WJG, Denning DW (2009) Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 12:141–147

    Article  PubMed  CAS  Google Scholar 

  57. White MH (1999) Antifungal agents. In: Armstrong DA, Cohen J (eds) Infectious diseases: fungal infections. Mosby-Wolfe, London

    Google Scholar 

  58. Wong-Beringer A, Jacobs RA, Guglielmo BJ (1998) Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27:603–618

    Article  PubMed  CAS  Google Scholar 

  59. Xue S, Gu R, Wu T, Zhang M, Wang X (2009) Oral potassium iodide for the treatment of sporotrichosis. Cochrane Database Syst Rev 4:CD006136

    PubMed  Google Scholar 

  60. Zonios DI, Bennett JE (2008) Update on azole antifungals. Semin Respir Crit Care Med 29:198–210

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Clinical Microbiology, Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, 44195, USA

    Gerri S. Hall Ph.D.

  2. Pharmacy Department, Cleveland Clinic, Cleveland, OH, USA

    Jennifer A. Sekeres Pharm.D. & Elizabeth Neuner Pharm.D.

  3. Staff Emeritus, Section of Podiatric Medicine, Cleveland Clinic, Cleveland, OH, USA

    James O. Hall D.P.M.

Authors
  1. Gerri S. Hall Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer A. Sekeres Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth Neuner Pharm.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James O. Hall D.P.M.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerri S. Hall Ph.D. .

Editor information

Editors and Affiliations

  1. Section of Clinical Microbiology, Department of Clinical Pathology, Cleveland Clinic, Euclid Ave. 9500, Cleveland, 44195, Ohio, USA

    Gerri S. Hall

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hall, G.S., Sekeres, J.A., Neuner, E., Hall, J.O. (2012). Antifungal Agents. In: Hall, G. (eds) Interactions of Yeasts, Moulds, and Antifungal Agents. Humana Press. https://doi.org/10.1007/978-1-59745-134-5_1

Download citation

Publish with us

Policies and ethics

Search

Navigation